Oura CEO talks potential IPO and ‘nonnegotiable’ data privacy

Oura Health CEO Tom Hale indicated the health-tracking ring maker is prepared for an IPO, citing significant growth and scale, with the company projecting $1 billion in revenue this year, doubling its 2024 figures, amidst unconfirmed reports of an $11 billion valuation. Hale confirmed a public offering is a strong option for Oura, while also emphasizing the company's non-negotiable commitment to user data privacy and security.

Analysis

Oura Health is signaling strong readiness for a public market debut, with CEO Tom Hale stating the company has met the necessary thresholds of size, trajectory, and growth for an IPO. This assertion is substantiated by a significant financial forecast: Oura expects to generate $1 billion in revenue this year, representing a 100% increase from its 2024 revenue. While the CEO did not comment on recent reports of a new funding round, the rumored valuation of nearly $11 billion provides a critical market benchmark, suggesting a forward Price-to-Sales multiple of approximately 11x based on the company's revenue guidance. Furthermore, management is proactively addressing a key industry risk by emphasizing that user data privacy and security are "nonnegotiable," a crucial stance for a health-tech company that could mitigate potential regulatory and reputational headwinds ahead of a public listing.

Key Decisions for Investors

• Investors tracking the private markets should interpret the CEO's comments as a strong indicator of a forthcoming IPO, warranting preliminary due diligence on the company's financials and competitive positioning.
• The projected 100% year-over-year revenue growth is a primary bullish indicator, though investors should weigh this against the implied 11x forward sales multiple to assess valuation relative to public technology and health-tech comparables.
• Monitor the company's execution on its data privacy commitments, as maintaining user trust is critical to sustaining its growth trajectory and mitigating long-term regulatory risk in the health-tech sector.